Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Editas Medicine

Editas Medicine, Inc. engages in the development and commercialization of genome editing technology. Its technology includes clustered, regularly interspaced short palindromic repeats (CRISPR), and CRISPR associated protein 9 (Cas9). The company was founded by Feng Zhang, Jennifer A. Doudna, George McDonald Church, J. Keith Joung and David R. Liu in September 2013 and is headquartered in Cambridge, MA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Editas Medicine reports positive clinical data and strategic advancements

Editas Medicine's Q4 2022 earnings call highlighted positive clinical data, strong financial positioning, and strategic advancements in genome editing medicines.
While facing challenges in hiring key personnel, regulatory negotiations, and strategic realignment, the company is well-positioned for therapeutic advancements and market growth.
Opportunities lie in replicating clinical success, strategic partnerships, and advancements in pipeline development, supported by strong collaborations and financial prospects.
Overall, Editas Medicine's performance, strengths, challenges, and opportunities reflect a company poised for continued growth and innovation in the genome editing space.

Editas Medicine excels in Q1 with promising trials and regulatory progress

Editas Medicine's Q1 performance was strong, supported by promising clinical trial data and regulatory advancements.
The company's focus on gene editing for hemoglobinopathies and strong IP position are key strengths.
Challenges include differentiation from competitors and legal uncertainties, while opportunities lie in expansion and regulatory progress.
Overall, Editas Medicine is well-positioned for growth in the gene editing market.

Editas Medicine reports positive data, raises funds, and faces challenges

Editas Medicine shows strong performance with positive clinical data and financial raise
Facing challenges in pipeline adjustment and FDA discussions for facility planning
Opportunities lie in expanding trials, partnerships, and enhancing R&D focus

Editas Medicine advances EDIT-301 program, poised for gene therapy leadership

Editas Medicine is making significant progress with EDIT-301, showcasing confidence in their gene editing capabilities and operational readiness.
While facing challenges in safety monitoring and differentiation, the company's strategic hires, strong IP portfolio, and focus on regulatory pathways provide a solid foundation for growth.
With a clear roadmap for clinical data presentation, manufacturing scaling, and regulatory submissions, Editas is well-positioned to capitalize on opportunities in gene editing therapies.

Editas Medicine exceeds enrollment goals and showcases promising clinical data

Editas Medicine's Q4 2023 Earnings Call showcased strong performance in enrollment, clinical data, and financials. The company's strengths lie in its research capabilities, cash position, and progress in key trials. Challenges include addressing analyst queries and optimizing manufacturing processes.

Editas Medicine reports robust Q1 performance and advances in gene editing

Editas Medicine's Q1 2024 performance reflects solid revenue and strong financial reserves, driven by R&D investments in the Renace program.
The company's strengths lie in its financial stability, advancing in vivo capabilities, and fostering strong collaborations for future growth.
Challenges include legal uncertainties, operational optimizations, and strategic complexities in therapeutic development.
Opportunities abound in driving Renace, regulatory progress for Reni-cel, and leveraging innovative in vivo approaches for unique indications.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Guardant Health Inc

Intuitive Surgical

Teladoc

Vertex Pharmaceuticals

SPDR S&P Biotech ETF

Why I'm Betting Big on This 1 Megatrend

CRISPR Therapeutics

Johnson & Johnson

SPDR S&P 500 ETF Trust

Vanguard Total Stock Market ETF

With a nest egg this sizable, you'll need to find more than one place to put your money so it keeps growing.

Where to Invest $1 Million Right Now

There are only a handful of large, well-established gene editors with robust and mature therapy pipelines in the world today. Of those, one that stands out is a $4.8 billion biotechnology company by the name of Editas Medicine (NASDAQ:EDIT).

A Play on the Biggest Scientific Breakthrough of the Century

CytomX Therapeutics

Inovio Pharmaceuticals

All four biotechs announced the pricing of stock offerings.

Why Editas Medicine, Inovio, Dyne, and CytomX Stocks Are Falling Today

Beam Therapeutics

Intellia Therapeutics

SpringWorks Therapeutics Inc

Among the public companies that made the BioSpace list of the top up and coming life sciences firms in 2019 and 2020, the majority have seen gains in their share prices. Given this metric, investors might want to track the progress of those still-private firms in the event they take the initial public offering route down the line.

Beam, SpringWorks Biggest Gainers on BioSpace List

Editas' (EDIT) lead candidate EDIT-101, that employs CRISPR gene editing to treat LCA10, holds potential. The company is also developing EDIT-301 for treating SCD.

Editas (EDIT) Up More Than 100% in Past 3 Months: Here's Why

AeroVironment

Grayscale Bitcoin Trust

Nano Dimension

Stratasys

LendingTree

Commentary from Ark Invest: We share weekly commentaries with investors on stocks in our strategies that have appreciated or dropped more than 15% in a day during the course of the week.

Ark Invest Stocks With Big Moves Last Week

Editas Medicine (EDIT) closed at $76.14 in the latest trading session, marking a +0.29% move from the prior day.

Editas Medicine (EDIT) Gains As Market Dips: What You Should Know

Cellectis SA

Calyxt

Sangamo Therapeutics

Between these seven genetic editing pioneers, you have the widest exposure to the biggest scientific breakthrough of the century. The post 7 CRISPR Stocks for the Future of Medicine appeared first on InvestorPlace.

7 CRISPR Stocks for the Future of Medicine

Despite a stellar 4x rise since the March 23 lows of last year, at the current price of around $73 per share we believe Editas Medicine, a biotechnology company focused on developing treatments using gene editing technology, looks attractive and it can see more upside from the current levels.

Despite A 4x Rise, Editas Medicine May Continue To Trend Higher

BioNTech SE

SmileDirectClub

Just because they did it in 2020 doesn't mean they won't outrun the market again in the new year.

3 Healthcare Stocks That Can Double Your Money in 2021

The FDA clears the initiation of the safety phase of Editas' (EDIT) early-stage study on investigational gene-editing therapy EDIT-301 for treating sickle cell disease. Shares down.

Editas (EDIT) Gets FDA Nod to Begin Safety Study on EDIT-301

One of the biotech's top executives is leaving.

Why Editas Medicine Stock Is Tumbling Today

Gene editing has emerged as a promising biotech theme. The technology is used to insert, edit, or delete a gene from an organism's genome, helping to replace the defective genes responsible for a medical condition with healthy versions.

CRISPR, Editas, Intellia: Gene Editing Stocks To Play The Next Revolution In Medicine

EDIT-301 is in development as a best-in-class, durable medicine for people living with sickle cell disease EDIT-301 is in development as a best-in-class, durable medicine for people living with sickle cell disease

Editas Medicine Announces the FDA has Cleared Initiation of the EDIT-301 Clinical Trial

CAMBRIDGE, Mass., Jan. 11, 2021 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today announced that its Chief Scientific Officer, Charles Albright, Ph.D., is stepping down from the Company on January 15 to pursue another opportunity. A search is underway to find a successor to Dr. Albright.

Editas Medicine Announces Transition of Chief Scientific Officer

A leading portfolio manager recently told Bloomberg Television that gene-editing companies may turn out to be better investment opportunities than Tesla Inc. (NASDAQ:TSLA).

Portfolio Manager Thinks Gene-Editing Stocks Could Outperform Tesla

Intellia Therapeutics offered an update Thursday for its gene-editing programs, helping boost genetics stocks Crispr Therapeutics, Editas Medicine, Fate Therapeutics and Beam Therapeutics. The post Genetics Stocks Pop After Intellia Offers Update For Gene-Editing Drugs appeared first on Investor's Business Daily.

Genetics Stocks Pop After Intellia Offers Update For Gene-Editing Drugs

FedEx

Lockheed Martin

Roku

Albertsons Companies

Arcturus Therapeutics

Big Lots

CME Group

3D Systems

Domino's Pizza

Over halfway through the trading day on Thursday, and the broad markets are making a run into the afternoon.

Domino's, FedEx, Lockheed, Roku and More of Tuesday Afternoon's Analyst Calls

Here we discuss three booming technological developments in the biotech sector, which can capture investor attention in 2021

3 Biotech Technological Developments to Watch Out For in 2021

BridgeBio Pharma Inc

Fate Therapeutics

Clinical trial readouts this year could cause these closely watched biotech stocks to explode overnight.

3 Biotech Stocks That Could Double Your Money in 2021

CAMBRIDGE, Mass., Jan. 04, 2021 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today announced that it will present a company overview at the 39th Annual J.P. Morgan Healthcare Conference, held virtually, on Wednesday, January 13, 2021, at 10:50 a.m. ET.

Editas Medicine to Present at the 39th Annual J.P. Morgan Healthcare Conference

CymaBay Therapeutics

Marinus Pharmaceuticals

Here we discuss five biotech stocks - EDIT, VRTX, NTLA, CBAY, MRNS - that could prove to be great investments in the long run.

5 Disruptive Biotech Stocks With Solid Long-Term Potential

Telesis Bio Inc

bluebird bio

Big drugmakers could be attracted to these smaller players with promising pipelines.

3 Top Biotech Buyout Candidates in 2021

The gene-editing stocks are being pulled down by a broader biotech sell-off.

News for Editas Medicine Stock (EDIT)